摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(4E)-2-ethyl-6-methyl-6,7-dihydro-1,3-benzoxazol-4(5H)-one oxime | 558476-78-1

中文名称
——
中文别名
——
英文名称
(4E)-2-ethyl-6-methyl-6,7-dihydro-1,3-benzoxazol-4(5H)-one oxime
英文别名
(NE)-N-(2-ethyl-6-methyl-6,7-dihydro-5H-1,3-benzoxazol-4-ylidene)hydroxylamine
(4E)-2-ethyl-6-methyl-6,7-dihydro-1,3-benzoxazol-4(5H)-one oxime化学式
CAS
558476-78-1
化学式
C10H14N2O2
mdl
——
分子量
194.233
InChiKey
FEUOKJIPNLYJBJ-KPKJPENVSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    14
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.6
  • 拓扑面积:
    58.6
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Benzothiazole-and benzoxazole-4, 7-dione derivatives and their use as dcd25 phosphatase inhibitors
    摘要:
    这项发明涉及将一般式(I)的化合物用作cdc25磷酸酶抑制剂,特别是cdc25-C磷酸酶和CD45磷酸酶,其中:W代表O或S。根据这项发明,一般式(I)的化合物特别可用于制备用于癌症治疗的药物。
    公开号:
    US20060040996A1
  • 作为产物:
    描述:
    参考文献:
    名称:
    Benzothiazole-and benzoxazole-4, 7-dione derivatives and their use as dcd25 phosphatase inhibitors
    摘要:
    这项发明涉及将一般式(I)的化合物用作cdc25磷酸酶抑制剂,特别是cdc25-C磷酸酶和CD45磷酸酶,其中:W代表O或S。根据这项发明,一般式(I)的化合物特别可用于制备用于癌症治疗的药物。
    公开号:
    US20060040996A1
点击查看最新优质反应信息

文献信息

  • Product comprising at least one phosphatase cdc25 inhibitor combined with at least one other anticancer agent
    申请人:Prevost Gregoire
    公开号:US20060281736A1
    公开(公告)日:2006-12-14
    A subject of the invention is a product comprising at least one Cdc25 phosphatase inhibitor in combination with at least one other anti-cancer agent for a therapeutic use which is simultaneous, separate or spread over time in the treatment of cancer. According to the invention, the other anti-cancer agent is preferably chosen from: analogues of DNA bases such as 5-fluorouracil; Type I and/or II topoisomerase inhibitors such as for example camptothecin and its analogues, doxorubicin or amsacrine; compounds interacting with the cell spindle such as for example paclitaxel (Taxol); compounds acting on the cytoskeleton such as vinblastine; inhibitors of the transduction of the signal passing through the heterotrimeric G proteins; prenyltransferase inhibitors, and in particular farnesyltransferase inhibitors; cyclin-dependent kinase (CDKs) inhibitors; alkylating agents such as cisplatin; antagonists of folic acid such as methotrexate; and inhibitors of the synthesis of DNA and cell division cell such as mitomycin C. A further subject of the invention is (1R)-1-[((2R)-2-amino-3-[(8S)-8-(cyclohexylmethyl)-2-phenyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl]-3-oxopropyl}dithio)methyl]-2-[(8S)-8-(cyclohexylmethyl)-2-phenyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8B)-yl]-2-oxoethylamine, or a pharmaceutically acceptable salt thereof, useful as an anticancer agent.
    本发明的一个主题是一种产品,包括至少一种Cdc25磷酸酶抑制剂与至少一种其他抗癌药物的组合,用于治疗癌症,治疗可以同时进行、分开进行或随时间推移进行。根据本发明,其他抗癌药物优选从以下选择:DNA碱基类似物,如5-氟尿嘧啶;I型和/或II型拓扑异构酶抑制剂,例如紫杉醇及其类似物、阿霉素或阿马曲辛;与细胞纺锤相互作用的化合物,例如紫杉醇(紫杉醇);作用于细胞骨架的化合物,如长春碱;通过异三聚体G蛋白传递的信号的抑制剂;前尾转移酶抑制剂,特别是法尼基转移酶抑制剂;细胞周期蛋白依赖性激酶(CDKs)抑制剂;碱化剂,如顺铂;叶酸拮抗剂,如甲氨蝶呤;以及DNA合成和细胞分裂细胞的抑制剂,如丝裂霉素C。本发明的另一个主题是(1R)-1-[((2R)-2-氨基-3-[(8S)-8-(环己甲基)-2-苯基-5,6-二氢咪唑[1,2-a]吡嗪-7(8H)-基]-3-氧代丙基}二硫)甲基]-2-[(8S)-8-(环己甲基)-2-苯基-5,6-二氢咪唑[1,2-a]吡嗪-7(8B)-基]-2-氧代乙基胺,或其药学上可接受的盐,用作抗癌剂。
  • Product comprising at least one Cdc25 phosphatase inhibitor in combination with at least one other anti-cancer agent
    申请人:Provost Gregoire
    公开号:US20090253685A1
    公开(公告)日:2009-10-08
    A subject of the invention is a product comprising at least one Cdc25 phosphatase inhibitor in combination with at least one other anti-cancer agent for a therapeutic use which is simultaneous, separate or spread over time in the treatment of cancer. According to the invention, the other anti-cancer agent is preferably chosen from: analogues of DNA bases such as 5-fluorouracil; Type I and/or II topoisomerase inhibitors such as for example camptothecin and its analogues, doxorubicin or armsacrine; compounds interacting with the cell spindle such as for example paclitaxel (Taxol); compounds acting on the cytoskeleton such as vinblastine; inhibitors of the transduction of the signal passing through the heterotrimeric G proteins; prenyltransferase inhibitors, and in particular farnesyltransferase inhibitors; cyclin-dependent kinase (CDKs) inhibitors; alkylating agents such as cisplatin; antagonists of folic acid such as methotrexate; and inhibitors of the synthesis of DNA and cell division cell such as mitomycin C. A further subject of the invention is (1R)-1-[((2R)-2-amino-3-[(8S)-8-(cyclohexylmethyl)-2-phenyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl]-3-oxopropyl}dithio)methyl]-2-[(8S)-8-(cyclohexylmethyl)-2-phenyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl]-2-oxoethylamine, or a pharmaceutically acceptable salt thereof, useful as an anticancer agent.
    本发明的一个主题是一种产品,其包含至少一种Cdc25磷酸酶抑制剂和至少一种其他抗癌药物的组合,用于治疗癌症的同时、分离或时间延长的治疗。根据本发明,其他抗癌药物优选从以下选择:DNA碱基类似物,例如5-氟尿嘧啶;I型和/或II型拓扑异构酶抑制剂,例如伯氨喹、多柔比星或阿姆沙曲;与细胞纺锤相互作用的化合物,例如紫杉醇(紫杉醇);作用于细胞骨架的化合物,例如长春新碱;通过异源三聚体G蛋白传递信号的抑制剂;戊二烯基转移酶抑制剂,特别是戊二烯基转移酶抑制剂;细胞周期蛋白依赖性激酶(CDKs)抑制剂;碱基化剂,例如顺铂;叶酸拮抗剂,例如甲氨蝶呤;以及DNA合成和细胞分裂细胞的抑制剂,例如丝裂霉素C。本发明的另一个主题是(1R)-1-[((2R)-2-氨基-3-[(8S)-8-(环己基甲基)-2-苯基-5,6-二氢咪唑[1,2-a]吡嗪-7(8H)-基]-3-氧代丙基}硫代)甲基]-2-[(8S)-8-(环己基甲基)-2-苯基-5,6-二氢咪唑[1,2-a]吡嗪-7(8H)-基]-2-氧代乙胺或其药学上可接受的盐,用作抗癌剂。
  • BENZOTHIAZOLE- AND BENZOOXAZOLE-4,7-DIONE, DERIVATIVES AND THEIR USE AS CDC25 PHOSPHATE INHIBITORS
    申请人:Galcera Contour Marie-Odile
    公开号:US20070255063A1
    公开(公告)日:2007-11-01
    Heterocyclic dione compounds as disclosed in the specification, compositions thereof and methods for the use thereof, for the treatment of T cell-mediated conditions such as autoimmune diseases and organ graft rejection.
    本发明涉及杂环二酮化合物及其组合物和使用方法,用于治疗T细胞介导的疾病,如自身免疫疾病和器官移植排斥反应。
  • BENZOOXAZOLE-4,7-DIONE, DERIVATIVES AND THEIR USE AS CDC25 PHOSPHATE INHIBITORS
    申请人:Galcera Contour Marie-Odile
    公开号:US20090131428A1
    公开(公告)日:2009-05-21
    The invention concerns the use as cdc25 phosphatase inhibitors, in particular cdc25-C phosphatase, and CD45 phosphatase, of compounds of general formula (I), wherein: W represents O or S. In accordance with the invention, the compounds of general formula (I) can in particular be used for preparing a medicine for cancer treatment.
    本发明涉及使用一般式(I)的化合物作为cdc25磷酸酶抑制剂,特别是cdc25-C磷酸酶和CD45磷酸酶的抑制剂,其中:W代表O或S。根据本发明,一般式(I)的化合物特别可用于制备治疗癌症的药物。
  • G-PROTEIN INHIBITOR
    申请人:PREVOST Gregoire
    公开号:US20090137596A1
    公开(公告)日:2009-05-28
    A subject of the invention is a product comprising at least one Cdc25 phosphatase inhibitor in combination with at least one other anti-cancer agent for a therapeutic use which is simultaneous, separate or spread over time in the treatment of cancer. According to the invention, the other anti-cancer agent is preferably chosen from: analogues of DNA bases such as 5-fluorouracil; Type I and/or II topoisomerase inhibitors such as for example camptothecin and its analogues, doxorubicin or amsacrine; compounds interacting with the cell spindle such as for example paclitaxel (Taxol); compounds acting on the cytoskeleton such as vinblastine; inhibitors of the transduction of the signal passing through the heterotrimeric G proteins; prenyltransferase inhibitors, and in particular farnesyltransferase inhibitors; cyclin-dependent kinase (CDKs) inhibitors; alkylating agents such as cisplatin; antagonists of folic acid such as methotrexate; and inhibitors of the synthesis of DNA and cell division cell such as mitomycin C. A further subject of the invention is (1R)-1-[((2R)-2-amino-3-[(8S)-8-(cyclohexylmethyl)-2-phenyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl]-3-oxopropyl}dithio)methyl]-2-[(8S)-8-(cyclohexylmethyl)-2-phenyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl]-2-oxoethylamine, or a pharmaceutically acceptable salt thereof, useful as an anticancer agent.
    本发明的一个主题是一种产品,包括至少一种Cdc25磷酸酶抑制剂与至少一种其他抗癌剂的组合,用于治疗癌症的同时、分开或分散在时间上。根据本发明,其他抗癌剂优选从以下选择:DNA碱基类似物,如5-氟尿嘧啶;I型和/或II型拓扑异构酶抑制剂,如例如喜树碱及其类似物,多柔比星或阿米替林;与细胞纺锤相互作用的化合物,例如紫杉醇(紫杉醇);作用于细胞骨架的化合物,例如长春新碱;通过异源三聚体G蛋白传递信号的抑制剂;戊烯基转移酶抑制剂,特别是法尼酰转移酶抑制剂;细胞周期蛋白依赖性激酶(CDKs)抑制剂;碱化剂,如顺铂;叶酸拮抗剂,如甲氨蝶呤;以及DNA合成和细胞分裂细胞的抑制剂,例如丝裂霉素C。本发明的另一个主题是(1R)-1-[((2R)-2-amino-3-[(8S)-8-(环己甲基)-2-苯基-5,6-二氢咪唑[1,2-a]吡嗪-7(8H)-基]-3-氧代丙基}二硫基)甲基]-2-[(8S)-8-(环己甲基)-2-苯基-5,6-二氢咪唑[1,2-a]吡嗪-7(8H)-基]-2-氧代乙基胺或其药学上可接受的盐,作为一种抗癌药物。
查看更多

同类化合物

伊莫拉明 (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5-氨基-1,3,4-噻二唑-2-基)甲醇 齐墩果-2,12-二烯[2,3-d]异恶唑-28-酸 黄曲霉毒素H1 高效液相卡套柱 非昔硝唑 非布索坦杂质Z19 非布索坦杂质T 非布索坦杂质K 非布索坦杂质E 非布索坦杂质67 非布索坦杂质65 非布索坦杂质64 非布索坦杂质61 非布索坦代谢物67M-4 非布索坦代谢物67M-2 非布索坦代谢物 67M-1 非布索坦-D9 非布索坦 非唑拉明 雷西纳德杂质H 雷西纳德 阿西司特 阿莫奈韦 阿米苯唑 阿米特罗13C2,15N2 阿瑞匹坦杂质 阿格列扎 阿扎司特 阿尔吡登 阿塔鲁伦中间体 阿培利司N-1 阿哌沙班杂质26 阿哌沙班杂质15 阿可替尼 阿作莫兰 阿佐塞米 镁(2+)(Z)-4'-羟基-3'-甲氧基肉桂酸酯 锌1,2-二甲基咪唑二氯化物 铵2-(4-氯苯基)苯并恶唑-5-丙酸盐 铬酸钠[-氯-3-[(5-二氢-3-甲基-5-氧代-1-苯基-1H-吡唑-4-基)偶氮]-2-羟基苯磺酸基][4-[(3,5-二氯-2-羟基苯 铁(2+)乙二酸酯-3-甲氧基苯胺(1:1:2) 钠5-苯基-4,5-二氢吡唑-1-羧酸酯 钠3-[2-(2-壬基-4,5-二氢-1H-咪唑-1-基)乙氧基]丙酸酯 钠3-(2H-苯并三唑-2-基)-5-仲-丁基-4-羟基苯磺酸酯 钠(2R,4aR,6R,7R,7aS)-6-(2-溴-9-氧代-6-苯基-4,9-二氢-3H-咪唑并[1,2-a]嘌呤-3-基)-7-羟基四氢-4H-呋喃并[3,2-D][1,3,2]二氧杂环己膦烷e-2-硫醇2-氧化物 野麦枯 野燕枯 醋甲唑胺